Physician profile
Atefeh Vafa
NPI 1316390321
$6,565.47
in general payments reported to CMS, 2019-2025
26 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2021: $1,139 · 2022: $1,866 · 2023: $1,362 · 2024: $931 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,428 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,428.29 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,763.94 | 2021-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $826.20 | 2021-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $727.27 | 2022-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $502.59 | 2021-2025 | |
| Glaxosmithkline, LLC. | $393.09 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $375.91 | 2021-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $370.17 | 2021-2023 | Acthar |
| Janssen Biotech, INC. | $276.78 | 2021-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $225.53 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $186.45 | 2022-2023 | Krystexxa |
| Lilly USA, LLC | $145.77 | 2021-2025 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $135.56 | 2022-2023 | |
| Celgene Corporation | $113.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $101.73 | 2021-2025 | Orencia |
| Sobi, INC | $81.39 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $76.96 | 2024-2025 | Tymlos |
| Fresenius Kabi USA, LLC | $42.56 | 2023-2024 | Idacio |
| Ani Pharmaceuticals, INC. | $37.38 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $29.75 | 2023 | Truxima |
| Tersera Therapeutics LLC | $27.37 | 2021 | |
| Fidia Pharma USA INC. | $26.64 | 2021-2024 | Hym/Hyn |
| Sandoz INC. | $23.01 | 2024 | Hyrimoz |
| Octapharma USA, INC. | $22.17 | 2021 | |
| Organon LLC | $20.84 | 2025 | Hadlima, Renflexis |
| United Therapeutics Corporation | $16.43 | 2024 | Tyvaso |
| Alexion Pharmaceuticals, INC. | $16.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atefeh Vafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.